Patents Assigned to HIDENSEQ
  • POLYMORPHISM IN THE BCL2 GENE DETERMINES RESPONSE TO CHEMOTHERAPY
    Publication number: 20170152569
    Abstract: Provided are methods useful for determining the expected efficacy of certain chemotherapy treatments and methods of treating cancer based on said determination. In particular, provides are methods and procedures of predicting the efficacy of paclitaxel treatments in cancer patients.
    Type: Application
    Filed: June 18, 2015
    Publication date: June 1, 2017
    Applicant: HIDENSEQ
    Inventors: Sol EFRONI, Alona ZILBERBERG, Rotem BEN-HAMO